{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:14:39Z","timestamp":1790280879500,"version":"4.1.0"},"reference-count":27,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Bill and Melinda Gates Foundation","award":["INV-001965"],"award-info":[{"award-number":["INV-001965"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Analytical methods for the quantification of the new 8-aminoquinoline antimalarial tafenoquine (TQ) in human blood, plasma and urine, and the 5,6-orthoquinone tafenoquine metabolite (5,6-OQTQ) in human plasma and urine have been validated. The procedure involved acetonitrile extraction of samples followed by ultra-high-performance liquid chromatography tandem mass spectrometry (UHPLC-MS\/MS). Chromatography was performed using a Waters Atlantis T3 column with a gradient of 0.1% formic acid and acetonitrile at a flow rate of 0.5 mL per minute for blood and plasma. Urine analysis was the same but with methanol containing 0.1% formic acid replacing acetonitrile mobile phase. The calibration range for TQ and 5,6-OQTQ in plasma was 1 to 1200 ng\/mL, and in urine was 10 to 1000 ng\/mL. Blood calibration range for TQ was 1 to 1200 ng\/mL. Blood could not be validated for 5,6-OQTQ due to significant signal suppression. The inter-assay precision (coefficient of variation %) was 9.9% for TQ at 1 ng\/mL in blood (n = 14) and 8.2% for TQ and 7.1% for 5,6-OQTQ at 1 ng\/mL in plasma (n = 14). For urine, the inter-assay precision was 8.2% for TQ and 6.4% for 5,6-OQTQ at 10 ng\/mL (n = 14). TQ and 5,6-OQTQ are stable in blood, plasma and urine for at least three months at both \u221280 \u00b0C and \u221220 \u00b0C. Once validated, the analytical methods were applied to samples collected from healthy volunteers who were experimentally infected with Plasmodium falciparum to evaluate the blood stage antimalarial activity of TQ and to determine the therapeutic dose estimates for TQ, the full details of which will be published elsewhere. In this study, the measurement of TQ and 5,6-OQTQ concentrations in samples from one of the four cohorts of participants is reported. Interestingly, TQ urine concentrations were proportional to parasite recrudescence times post dosing To our knowledge, this is the first description of a fully validated method for the measurement of TQ and 5,6-OQTQ quantification in urine.<\/jats:p>","DOI":"10.3390\/molecules27238186","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T03:34:24Z","timestamp":1669347264000},"page":"8186","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Quantification of Tafenoquine and 5,6-Orthoquinone Tafenoquine by UHPLC-MS\/MS in Blood, Plasma, and Urine, and Application to a Pharmacokinetic Study"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6593-1514","authenticated-orcid":false,"given":"Geoffrey W.","family":"Birrell","sequence":"first","affiliation":[{"name":"Drug Evaluation, Australian Defence Force Malaria and Infectious Disease Institute, Brisbane 4051, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Van Breda","sequence":"additional","affiliation":[{"name":"Drug Evaluation, Australian Defence Force Malaria and Infectious Disease Institute, Brisbane 4051, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Barber","sequence":"additional","affiliation":[{"name":"Clinical Malaria Group, QIMR Berghofer Medical Research Institute, Brisbane 4006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Webster","sequence":"additional","affiliation":[{"name":"Clinical Malaria Group, QIMR Berghofer Medical Research Institute, Brisbane 4006, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Clinical Malaria Group, QIMR Berghofer Medical Research Institute, Brisbane 4006, Australia"},{"name":"Department of Infectious Diseases, University of Melbourne, Melbourne 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Dennis","family":"Shanks","sequence":"additional","affiliation":[{"name":"Drug Evaluation, Australian Defence Force Malaria and Infectious Disease Institute, Brisbane 4051, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Edstein","sequence":"additional","affiliation":[{"name":"Drug Evaluation, Australian Defence Force Malaria and Infectious Disease Institute, Brisbane 4051, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1001\/jama.1952.72930340017010","article-title":"Mass therapy of subclinical vivax malaria with primaquine","volume":"149","author":"Alving","year":"1952","journal-title":"J. Am. Med. Assoc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1471-4922(03)00005-9","article-title":"Can primaquine therapy for vivax malaria be improved?","volume":"19","author":"Baird","year":"2003","journal-title":"Trends Parasitol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12936-019-2658-5","article-title":"Formation primaquine-5,6-orthoquinone, the putative active and toxic metabolite of primaquine via direct oxidation in human erythrocytes","volume":"18","author":"Fasinu","year":"2019","journal-title":"Malar. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e00711-18","DOI":"10.1128\/AAC.00711-18","article-title":"Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial","volume":"62","author":"Thakkar","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.124.3220.484.b","article-title":"Enzymatic deficiency in primaquine-sensitive erythrocytes","volume":"124","author":"Alving","year":"1956","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(08)60073-2","article-title":"Glucose-6-phosphate dehydrogenase deficiency","volume":"371","author":"Cappellini","year":"2008","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3390\/oxygen2040030","article-title":"RONS and Oxidative Stress: An Overview of Basic Concepts","volume":"2","year":"2022","journal-title":"Oxygen"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0940-2993(99)80010-4","article-title":"Metabolism of primaquine by liver homogenate fractions. Evidence for monoamine oxidase and cytochrome P450 involvement in the oxidative deamination of primaquine to carboxyprimaquine","volume":"51","author":"Constantino","year":"1999","journal-title":"Exp. Toxicol. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1038\/s41467-019-11239-0","article-title":"Antimalarial activity of primaquine operates via a two-step biochemical relay","volume":"10","author":"Camarda","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/1475-2875-13-507","article-title":"Enantioselective metabolism of primaquine by human CYP2D6","volume":"13","author":"Fasinu","year":"2014","journal-title":"Malar. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1128\/AAC.00343-15","article-title":"Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics","volume":"59","author":"Vuong","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Pookmanee, W., Thongthip, S., Tankanitlert, J., Mungthin, M., Sukasem, C., and Wittayalertpanya, S. (2021). Simplified and Rapid Determination of Primaquine and 5,6-Orthoquinone Primaquine by UHPLC-MS\/MS: Its Application to a Pharmacokinetic Study. Molecules, 26.","DOI":"10.3390\/molecules26144357"},{"key":"ref_13","first-page":"274","article-title":"A 2-part study to evaluate the asexual blood stage antimalarial activity, and the transmission blocking activity, of a single oral dose of tafenoquine in healthy subjects experimentally infected with plasmodium falciparum","volume":"105","author":"Barber","year":"2021","journal-title":"Am. J. Soc. Trop. Med. Hyg."},{"key":"ref_14","unstructured":"European Medicines Agency (2022, September 29). Guideline on Bioanalytical Method Validation. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-bioanalytical-method-validation_en.pdf."},{"key":"ref_15","unstructured":"Department of Health and Human Services. US Food and Drug Administration (2022, September 29). Bioanalytical Method Validation: Guidance for Industry, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioanalytical-method-validation-guidance-industry."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1128\/AAC.42.5.1293","article-title":"Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial","volume":"42","author":"Brueckner","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0378-4347(00)81111-1","article-title":"Rapid and sensitive quantitative analysis of the new antimalarial N4-[2,6-dimethoxy-4-methyl-5-[(3-trifluoromethyl)phenoxy]-8- quinolinyl]-1,4-pentanediamine in plasma by liquid chromatography and electrochemical detection","volume":"424","author":"Karle","year":"1988","journal-title":"J. Chromatogr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/00007691-200004000-00008","article-title":"Measurement of tafenoquine (WR 238605) in human plasma and venous and capillary blood by high-pressure liquid chromatography","volume":"22","author":"Kocisko","year":"2000","journal-title":"Ther. Drug Monit."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Araujo-Leon, J.A., Ortiz-Andrade, R., Vera-Sanchez, R.A., Oney-Montalvo, J.E., Coral-Martinez, T.I., and Cantillo-Ciau, Z. (2020). Development and Optimization of a High Sensitivity LC-MS\/MS Method for the Determination of Hesperidin and Naringenin in Rat Plasma: Pharmacokinetic Approach. Molecules, 25.","DOI":"10.3390\/molecules25184241"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.4155\/bio-2019-0041","article-title":"Microsampling: Considerations for its use in pharmaceutical drug discovery and development","volume":"11","author":"Spooner","year":"2019","journal-title":"Bioanalysis"},{"key":"ref_21","first-page":"1","article-title":"A Pharmacometrics Approach to Assess the Feasibility of Capillary Microsampling to Replace Venous Sampling in Clinical Studies: Tafenoquine Case Study","volume":"1","author":"Bachhav","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/bmc.1557","article-title":"Analysis of primaquine and its metabolite carboxyprimaquine in biological samples: Enantiomeric separation, method validation and quantification","volume":"25","author":"Avula","year":"2011","journal-title":"Biomed. Chromatogr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1002\/elps.200305632","article-title":"Recent advances in the determination of enantiomeric drugs and their metabolites in biological fluids by capillary electrophoresis-mediated microanalysis","volume":"24","author":"Bonato","year":"2003","journal-title":"Electrophoresis"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4269\/ajtmh.20-0061","article-title":"Prevalence of CYP2D6 Genotypes and Predicted Phenotypes in a Cohort of Cambodians at High Risk for Infections with Plasmodium vivax","volume":"103","author":"Spring","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/00008571-199712000-00003","article-title":"CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication","volume":"7","author":"Kohler","year":"1997","journal-title":"Pharmacogenetics"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e181449","DOI":"10.1001\/jamanetworkopen.2018.1449","article-title":"Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype with Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria","volume":"1","author":"Baird","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12936-016-1145-5","article-title":"Tafenoquine treatment of Plasmodium vivax malaria: Suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial","volume":"15","author":"Xue","year":"2016","journal-title":"Malar. J."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/23\/8186\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:25:59Z","timestamp":1760145959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/23\/8186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":27,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["molecules27238186"],"URL":"https:\/\/doi.org\/10.3390\/molecules27238186","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,24]]}}}